ATNM

Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) yesterday and set a price target of $25.00. The company's shares closed last Monday at $6.95. According to TipRanks.com, Cross is a 3-star analyst with an average return of 1.5% and a 35.4% success rate. Cross covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Syros Pharmaceuticals, and Aldeyra Therapeutics. Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.00, a 414.0% upside from current levels. In a report issued on April 12, H.C.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-receives-a-buy-from-alliance-global-partners?utm_source=advfn.com&utm_medium=referral